LIS
NBIX icon

Legacy Investment Solutions’s Neurocrine Biosciences NBIX Stock Holding History

Legacy Investment Solutions’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		$1.76K Buy
+14
New +$1.61K ﹤0.01% 533
2024
Q4 		$1.72K Hold
14
– – ﹤0.01% 519
2024
Q3 		$1.76K Buy
+14
New +$1.92K ﹤0.01% 492

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Legacy Investment Solutions's NBIX Position: Q2 2025 in Review

Legacy Investment Solutions opened a new position in Neurocrine Biosciences (NBIX) in Q2 2025: 14 shares worth $1.76K. The stake represents ﹤0.01% of the portfolio and ranks #533 among its holdings. This is a return to the name: Legacy Investment Solutions previously reported a position in NBIX as recently as Q4 2024.

Legacy Investment Solutions first reported a position in NBIX in Q3 2024 and has held it in 3 quarters since. 585 funds tracked by Wall St. Rank hold NBIX as of Q2 2025.

  • Legacy Investment Solutions held 14 shares of Neurocrine Biosciences worth $1.76K as of Q2 2025.
  • Neurocrine Biosciences was a new Legacy Investment Solutions position in Q2 2025.
  • Neurocrine Biosciences made up ﹤0.01% of Legacy Investment Solutions's portfolio in Q2 2025, its #533 holding.
  • Legacy Investment Solutions first reported a position in Neurocrine Biosciences in Q3 2024 and has held it in 3 quarters since.
  • 585 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2025.

Based on Legacy Investment Solutions's 13F filing for Q2 2025, filed 6 Aug 2025.